Compare LGN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGN | VCEL |
|---|---|---|
| Founded | 1963 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2025 | 1997 |
| Metric | LGN | VCEL |
|---|---|---|
| Price | $48.45 | $39.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $43.43 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 1.1M | 520.7K |
| Earning Date | 11-14-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $2,361,064,000.00 | $258,716,999.00 |
| Revenue This Year | $17.08 | $17.86 |
| Revenue Next Year | $32.52 | $18.55 |
| P/E Ratio | ★ N/A | $158.71 |
| Revenue Growth | ★ 46.19 | 14.05 |
| 52 Week Low | $26.96 | $29.24 |
| 52 Week High | $50.20 | $63.00 |
| Indicator | LGN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.83 |
| Support Level | N/A | $35.85 |
| Resistance Level | N/A | $39.07 |
| Average True Range (ATR) | 0.00 | 1.86 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 61.79 |
Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.